NFL Biosciences S.A.
ALNFL.PA
Euronext Paris0.98
EUR
- -
- -
NFL Biosciences S.A.
ALNFL.PA
(Euronext Paris)
Recent
price
0.98
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- NFL Biosciences S.A. (ALNFL.PA) is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions, including tobacco use disorder and excessive alcohol consumption; its lead product, NFL-101, is a patented, nicotine-free tobacco leaf protein extract in Phase 2b clinical trials for smoking cessation with positive results published in Nicotine & Tobacco Research confirming reduced craving and prolonged efficacy; NFL-301 targets alcohol use reduction and is in preclinical development from a traditional Chinese medicine plant; the company employs an outsourced research model to advance its pipeline toward licensing to larger pharmaceutical partners. Founded in 2006 and headquartered at 199 Rue Hélène Boucher, Castelnau-le-Lez, France, NFL Biosciences operates primarily in Europe with international clinical ambitions including FDA interactions in the United States. Recent developments include a successful €3 million capital increase in May 2025 following an initial €2.2 million offering; €1.2 million in non-dilutive funding secured in July 2025 from Bpifrance and banking partners to support NFL-101 manufacturing, preclinical work, and Phase 3 preparation; scientific collaborations with McLean Hospital and CEA yielding new mechanism-of-action data and prolonged activity insights; expansion of its scientific committee with global experts and appointment of a Chief Medical Officer in 2025; and receipt of scientific advice from European agencies and the FDA in October 2025 outlining NFL-101's development plan.